
Anthropic reports early results from using Claude across drug development with six companies
A shorter CAR-T design, 35,000 antibody candidates in a month and a manufacturing review that caught issues people missed. The results are early and mostly preclinical, and Anthropic now owns a small drug programme of its own.










